Business
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
Insilico Medicine ("Insilico"), a clinical-stage, generative artificial intelligence (AI)-driven biotechnology company, today announced that it has received USD 5 million from Menarini Group ("Menarini") as an additional milestone payment, following the completion of first-in-patient dosing in a Phase 1 study of MEN2501, which was licensed to Menarini in January 2025. MEN2501 (previously known as ISM9682) is a highly differentiated small molecule inhibitor of kinesin KIF18A motor protein with po
About this update from Insilico Medicine Cayman Topco
[{"type":"text","content":"Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment of USD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in development for chromosomally unstable solid tumors designed using Insilico's generative AI engine.","length":405,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Feb. 3, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage, generative artificial intelligence (AI)-driven biotechnology company, today announced that it has received USD 5 million from Menarini Group ("Menarini") as an additional milestone payment, following the completion of first-in-patient dosing in a Phase 1 study of MEN2501, which was licensed to Menarini in January 2025. MEN2501 (previously known as ISM9682) is a highly differentiated small molecule inhibitor of kinesin KIF18A motor protein with potent activity in cancers with chromosome instability.","length":620,"tagName":"p"},{"type":"text","content":"As part of a strategic collaboration to accelerate the development and delivery of transformative cancer therapies, the asset was subsequently licensed to Stemline Therapeutics, Inc. ("Stemline"), a wholly owned subsidiary of the Menarini Group, with the combined value of the agreements exceeding USD 550 million. Pursuant to the partnership, both parties actively advanced the program transition and subsequent development activities. Following IND approval for this program, Insilico received the first development and regulatory milestone payment of USD 3 million in July 2025.","length":591,"tagName":"p"},{"type":"text","content":""The program rapidly advanced into a Phase I clinical trial and successfully completed first patient dosing, fully demonstrating Menarini and Stemline's exceptional agility and clinical expertise," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "This milestone shows our shared commitment to delivering innovative therapies for cancer treatment. We are proud to further strengthen our partnership and encouraged to see AI-discovered drug candidates reaching such a critical stage, bringing us closer to providing novel treatment options for patient...